17 Years After Viagra, the Female Viagra May Finally Be Here

Flibanserin, a drug to treat low sexual desire in women.Allen Breed/AP

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


A contentious effort to introduce a sex-drive drug for women may be nearing a climax. After rejecting “the pink Viagra” (AKA flibanserin) twice in the past five years, a Federal Drug Administration advisory committee voted today that the the pill should be approved if measures are taken to reduce its potential side effects, such as low blood pressure and fainting.

The nonhormonal drug, developed by Sprout Pharmaceutical, is meant to be taken nightly. The company says it works by altering chemicals in the brain to increase a woman’s sexual desire (unlike Viagra, which increases blood flow to certain parts of the body). Women who took the drug in trials reported no more than one additional “sexually satisfying event” per month than women who received a placebo.

Women who took the drug in trials reported no more than one additional “sexually satisfying event” per month than women who received a placebo.

Today’s vote comes 17 years after the FDA approved Viagra, the incredibly profitable erectile dysfunction treatment. Since then, more than two dozen prescription drugs have been approved to assist with male sexual performance, but none for women.

Even the Score, a group backed by the pharmaceutical companies that developed flibanserin, says that women also suffer from sexual dysfunction and that the unwillingness to develop and approve drugs to treat it is a matter of bias. They called today’s vote a victory for gender equality. “Women with Hypoactive Sexual Desire Disorder deserve the safety and peace of mind that comes with access to FDA-approved medical treatment options, and today we write a new chapter in the fight for equity in sexual health,” Even the Score said in a statement.

But others believe that potentially profitable drugs for a dubious disorder are being pushed with little proven effectiveness. “I don’t think there is anything sexist about denying approval for drugs that don’t have an adequate risk-to-benefit ratio,” Thea Cacchioni, a professor of women’s studies at the University of Victoria in British Columbia, told the New York Times. According to Forbes, $50 million in private investment rest on flibanserin’s approval.

The FDA is expected to come to a final decision on the drug in August.

GREAT JOURNALISM, SLOW FUNDRAISING

Our team has been on fire lately—publishing sweeping, one-of-a-kind investigations, ambitious, groundbreaking projects, and even releasing “the holy shit documentary of the year.” And that’s on top of protecting free and fair elections and standing up to bullies and BS when others in the media don’t.

Yet, we just came up pretty short on our first big fundraising campaign since Mother Jones and the Center for Investigative Reporting joined forces.

So, two things:

1) If you value the journalism we do but haven’t pitched in over the last few months, please consider doing so now—we urgently need a lot of help to make up for lost ground.

2) If you’re not ready to donate but you’re interested enough in our work to be reading this, please consider signing up for our free Mother Jones Daily newsletter to get to know us and our reporting better. Maybe once you do, you’ll see it’s something worth supporting.

payment methods

GREAT JOURNALISM, SLOW FUNDRAISING

Our team has been on fire lately—publishing sweeping, one-of-a-kind investigations, ambitious, groundbreaking projects, and even releasing “the holy shit documentary of the year.” And that’s on top of protecting free and fair elections and standing up to bullies and BS when others in the media don’t.

Yet, we just came up pretty short on our first big fundraising campaign since Mother Jones and the Center for Investigative Reporting joined forces.

So, two things:

1) If you value the journalism we do but haven’t pitched in over the last few months, please consider doing so now—we urgently need a lot of help to make up for lost ground.

2) If you’re not ready to donate but you’re interested enough in our work to be reading this, please consider signing up for our free Mother Jones Daily newsletter to get to know us and our reporting better. Maybe once you do, you’ll see it’s something worth supporting.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate